ASP 5633

Drug Profile

ASP 5633

Alternative Names: ASP-5633

Latest Information Update: 19 Nov 2015

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Stress incontinence

Most Recent Events

  • 21 Oct 2015 Phase-I development for Stress incontinence is ongoing in Japan
  • 01 Oct 2015 Discontinued - Phase-I for Stress incontinence in Japan (PO)
  • 01 Aug 2014 Phase-I clinical trials in Stress incontinence in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top